Stocktoria
Lineage Cell Therapeutics, Inc. LCTX
NYSE American · XASE · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1992-03-05
Lineage Cell Therapeutics, Inc. financials (annual, from 10-K)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.6M | $9.5M | $8.9M | $14.7M | $4.3M | $1.8M | $3.5M | $5.0M | $3.5M | $5.9M |
| Gross profit | — | — | $8.3M | $14.0M | $2.9M | $1.4M | $3.1M | $4.7M | $3.3M | $5.6M |
| R&D expense | $17.7M | $12.5M | $15.7M | $14.0M | $33.9M | $12.3M | $17.9M | $21.0M | $24.0M | $36.1M |
| Operating income | -$36.6M | -$21.5M | -$24.7M | -$22.5M | -$49.2M | -$26.4M | -$38.9M | -$41.8M | -$38.9M | -$59.0M |
| Income tax | -$5.3M | $0 | -$1.8M | $541,000 | — | -$1.2M | -$7.4M | $346,000 | — | — |
| Net income | -$63.5M | -$18.6M | -$21.5M | -$26.3M | -$43.0M | -$20.6M | -$11.7M | -$46.0M | -$20.0M | $33.6M |
| EPS (diluted) | $-0.28 | $-0.09 | $-0.12 | $-0.15 | — | — | — | — | $-0.17 | $0.34 |
| Operating cash flow | -$18.9M | -$23.1M | -$28.6M | $1.1M | -$23.6M | -$19.8M | -$31.9M | -$30.9M | -$30.5M | -$42.3M |
| Free cash flow | -$19.4M | -$23.7M | -$29.2M | $646,000 | -$23.9M | -$19.8M | -$32.4M | -$31.4M | -$31.8M | -$44.6M |
| Cash & equivalents | $40.8M | $45.8M | $35.4M | $11.4M | $55.7M | $32.6M | $9.5M | $23.6M | $36.8M | $22.1M |
| Total assets | $112.6M | $113.2M | $101.0M | $123.7M | $174.5M | $107.9M | $125.5M | $101.7M | $173.2M | $142.6M |
| Total liabilities | $69.2M | $36.2M | $39.0M | $51.7M | $83.6M | $12.8M | $14.2M | $9.4M | $9.0M | $12.1M |
| Shareholders' equity | $44.5M | $78.4M | $63.4M | $73.3M | $92.2M | $96.2M | $113.0M | $92.2M | $164.3M | $130.5M |
Growth · year-over-year · Revenue CAGR 10.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +53.2% | +6.2% | -39.2% | +238.7% | +137.7% | -48.1% | -29.5% | +44.2% | -41.6% | -15.8% |
| Net income growth | — | — | — | — | — | — | — | — | -159.5% | — |
| EPS growth | — | — | — | — | — | — | — | — | -150.0% | — |
| Free cash flow growth | — | — | -4626.3% | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0000876343 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.